OpenNashEarnings

ResMed (RMD) · Medical Devices

ResMed Q4 FY2026 earnings: summary, key numbers & outlook

Results filed 6 Aug 2026 · Quarter ended 30 Jun 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

ResMed completed its Noctrix Health acquisition for restless legs wearables, agreed to sell MatrixCare, and partnered with ŌURA while launching AirSense 11 in Taiwan.

ResMed ended fiscal 2026 with demand strong across sleep devices, masks, accessories and software. Americas and Rest of World sleep businesses both grew, while Residential Care Software grew only modestly. It completed the Noctrix Health acquisition, which adds an FDA De Novo classified wearable therapy for Restless Leg Syndrome, and partnered with ŌURA on sleep health education and pathways to care.

Management says it will use its global scale and enhance its digital capabilities to improve patient outcomes and reduce healthcare costs. The portfolio is being narrowed: the MatrixCare business is being sold, with closing expected in the first quarter of fiscal 2027. The main risk is execution: integrating a new device category while a $42 million Astral field safety notification shows quality issues can carry costs.

Key numbers

Q4 revenue · GAAP
$1.5B

up 9% from a year ago

Q4 net income · GAAP
$383.0M

up 1% from a year ago

Q4 diluted EPS · GAAP
$2.64

up 2% from a year ago

Q4 non-GAAP diluted EPS · non-GAAP
$2.95

up 16% from a year ago

Q4 gross margin · GAAP
58.8%

down 200 bps from a year ago

Q4 non-GAAP gross margin · non-GAAP
62.3%

up 90 bps from a year ago

Q4 income from operations · GAAP
$449.0M

down 1% from a year ago

Q4 operating margin · GAAP
30.7%

down 300 bps from a year ago

Segment or metricValueChange
Americas Sleep and Breathing Health$853.0Mup 8%
Rest of World Sleep and Breathing Health$439.0Mup 13%, up 10% in constant currency
Total devices$750.0Mup 8%, up 7% in constant currency
Masks and other$542.0Mup 11%, up 10% in constant currency
Residential Care Software$172.0Mup 3%, up 2% in constant currency
Where each number comes from
  • Q4 revenue: “Revenue | $1,464 | $1,348 | 9% | 8% Gross margin | 58.8% | 60.8% | (200) bps Non-GAAP gross margin (B) | 62.3% | 61.4% | 90 bps”
  • Q4 net income: “Operating margin | 30.7% | 33.7% | (300) bps Non-GAAP income from operations (B) | 515 | 476 | 8 Non-GAAP operating margin | 35.2% | 35.3% | (10) bps Net income | 383 | 380 | 1”
  • Q4 diluted EPS: “Non-GAAP net income (B) | 428 | 375 | 14 Diluted earnings per share | $2.64 | $2.58 | 2 Non-GAAP diluted earnings per share (B) | $2.95 | $2.55 | 16”
  • Q4 non-GAAP diluted EPS: “Diluted earnings per share | $2.64 | $2.58 | 2 Non-GAAP diluted earnings per share (B) | $2.95 | $2.55 | 16 Operating cash flow | 455 | 539 | (16)”
  • Q4 gross margin: “Revenue | $1,464 | $1,348 | 9% | 8% Gross margin | 58.8% | 60.8% | (200) bps Non-GAAP gross margin (B) | 62.3% | 61.4% | 90 bps”
  • Q4 non-GAAP gross margin: “Gross margin | 58.8% | 60.8% | (200) bps Non-GAAP gross margin (B) | 62.3% | 61.4% | 90 bps Research and development expenses | 106 | 86 | 22 | 19”
  • Q4 income from operations: “Non-GAAP selling, general, and administrative expenses(B) | 291 | 265 | 10 | 7 Income from operations | 449 | 455 | (1) Operating margin | 30.7% | 33.7% | (300) bps”
  • Q4 operating margin: “Income from operations | 449 | 455 | (1) Operating margin | 30.7% | 33.7% | (300) bps Non-GAAP income from operations (B) | 515 | 476 | 8”
  • Americas Sleep and Breathing Health: “Masks and other | 394 | 359 | 10 Total Americas (C) | $853 | $792 | 8 Rest of World (C) Devices | $291 | $261 | 12% | 9%”
  • Rest of World Sleep and Breathing Health: “Masks and other | 148 | 128 | 16 | 12 Total Rest of World (C) | $439 | $389 | 13 | 10 Global revenue Total Devices”
  • Total devices: “Global revenue Total Devices | $750 | $694 | 8% | 7% Total Masks and other | 542 | 487 | 11 | 10 Total Sleep and Breathing Health”
  • Masks and other: “Total Devices | $750 | $694 | 8% | 7% Total Masks and other | 542 | 487 | 11 | 10 Total Sleep and Breathing Health | $1,292 | $1,181 | 9 | 8”
  • Residential Care Software: “Total Sleep and Breathing Health | $1,292 | $1,181 | 9 | 8 Residential Care Software | 172 | 167 | 3 | 2 Total | $1,464 | $1,348 | 9 | 8”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ4 FY2026vs year agovs last quarter
Revenue$1.5B+8.6%+2.3%
Operating income$448.7M−1.3%−10.2%
Net income$383.4M+1.0%−3.8%
Free cash flow$403.5M−20.6%−22.5%
Gross margin58.8%−2.0 pts−3.4 pts
Operating margin30.7%−3.0 pts−4.2 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Capital to be returned to shareholdersfiscal year 2027more than $1.85 billion

Key takeaways

  1. Noctrix deal extends ResMed beyond sleep apnea

    ResMed completed the acquisition of Noctrix Health, which sells FDA De Novo classified wearable therapeutics for Restless Leg Syndrome. This adds a new condition and device category to its home-care portfolio.

  2. MatrixCare sale narrows the software portfolio

    ResMed agreed to sell its MatrixCare business, with closing expected in the first quarter of fiscal 2027. Residential Care Software grew only 2% in constant currency, so the sale points to a sharper focus on sleep and breathing health.

  3. ŌURA partnership targets sleep care pathways

    ResMed partnered with ŌURA to expand access to sleep health education and pathways to care. It is a consumer-facing route to bring more people into diagnosis and treatment.

  4. Masks and accessories outgrew devices

    Masks and other grew 10% in constant currency against 7% for devices. Demand was described as strong across devices, masks, accessories and software.

  5. Astral safety notification shows a quality cost

    ResMed booked $42 million of Astral field safety notification expenses, which is the main reason GAAP gross margin of 58.8% trailed non-GAAP gross margin of 62.3%. It shows product-quality events can affect profitability even as productivity gains continue.

Charts

Revenue$1.5B+8.6% y/yQ4 FY26
Q2 FY25: $1.3BQ2 25$1.3BQ3 FY25: $1.3BQ3 25$1.3BQ4 FY25: $1.3B (worked out from the annual figure)Q4 25$1.3BQ1 FY26: $1.3BQ1 26$1.3BQ2 FY26: $1.4BQ2 26$1.4BQ3 FY26: $1.4BQ3 26$1.4BQ4 FY26: $1.5B (worked out from the annual figure)Q4 26$1.5BQ1 FY27: $1.4BQ1 27$1.4B

Fourth quarter worked out from the annual figure.

Data
Q2 FY25$1.3B
Q3 FY25$1.3B
Q4 FY25$1.3B *
Q1 FY26$1.3B
Q2 FY26$1.4B
Q3 FY26$1.4B
Q4 FY26$1.5B *
Q1 FY27$1.4B
Diluted EPS (GAAP)$2.92+23.2% y/yQ1 FY27
Q2 FY25: $2.34Q2 25$2.34Q3 FY25: $2.48Q3 25$2.48Q1 FY26: $2.37Q1 26$2.37Q2 FY26: $2.68Q2 26$2.68Q3 FY26: $2.74Q3 26$2.74Q1 FY27: $2.92Q1 27$2.92
Data
Q2 FY25$2.34
Q3 FY25$2.48
Q1 FY26$2.37
Q2 FY26$2.68
Q3 FY26$2.74
Q1 FY27$2.92

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin30.7%−3.0 pts y/yQ4 FY26
Q2 FY25: 32.5%Q2 2532.5%Q3 FY25: 33.0%Q3 2533.0%Q4 FY25: 33.7%Q4 2533.7%Q1 FY26: 33.4%Q1 2633.4%Q2 FY26: 34.6%Q2 2634.6%Q3 FY26: 34.9%Q3 2634.9%Q4 FY26: 30.7%Q4 2630.7%Q1 FY27: 32.0%Q1 2732.0%
Data
Q2 FY2532.5%
Q3 FY2533.0%
Q4 FY2533.7%
Q1 FY2633.4%
Q2 FY2634.6%
Q3 FY2634.9%
Q4 FY2630.7%
Q1 FY2732.0%
Free cash flow$403.5M−20.6% y/yQ4 FY26
Q2 FY25: $288.0MQ2 25$288.0MQ3 FY25: $557.9MQ3 25$557.9MQ4 FY25: $508.2MQ4 25$508.2MQ1 FY26: $414.4MQ1 26$414.4MQ2 FY26: $311.2MQ2 26$311.2MQ3 FY26: $520.5MQ3 26$520.5MQ4 FY26: $403.5MQ4 26$403.5MQ1 FY27: $373.7MQ1 27$373.7M
Data
Q2 FY25$288.0M
Q3 FY25$557.9M
Q4 FY25$508.2M
Q1 FY26$414.4M
Q2 FY26$311.2M
Q3 FY26$520.5M
Q4 FY26$403.5M
Q1 FY27$373.7M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What did ResMed do to expand its product portfolio this quarter?

It completed the acquisition of Noctrix Health, which sells FDA De Novo classified wearable therapeutics for Restless Leg Syndrome. It also launched AirCurve 11 ST/ST-A in the U.S. and AirTouch F30i Comfort in Brazil and Chile.

What is happening to ResMed's MatrixCare business?

ResMed agreed to sell MatrixCare, with the transaction expected to close in the first quarter of its fiscal year 2027.

Where is ResMed expanding AirSense 11?

It launched AirSense 11 in Taiwan, following other launches in APAC, EMEA and the Americas.

Why did ResMed partner with ŌURA?

The partnership aims to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health.

Which parts of the business grew fastest in the quarter?

In constant currency, Rest of World Sleep and Breathing Health grew 10% and masks and other grew 10%, while Residential Care Software grew 2%.

Documents

From ResMed investor relations

SEC filing